TGFB1 and migraine disorder: Patients diagnosed with episodic migraine (n = 40) were randomly assigned to receive 80 mg/day of nano-curcumin or placebo for 2 months. Gene expression and serum levels of TGF-b and IL-4 in PBMCs isolated from the migraine patients were determined via real-time PCR and ELISA, respectively.